Literature DB >> 9843440

Characterization of the extracellular ligand-binding domain of the type II activin receptor.

J Greenwald1, V Le, A Corrigan, W Fischer, E Komives, W Vale, S Choe.   

Abstract

The binding of a ligand to cell surface receptors initiates a cascade of intracellular signals that generate responses to the external stimuli. Thus, this event plays a pivotal role in the mechanism of transmembrane signaling. Activin is a member of a cytokine family that is involved in diverse biological processes. To study the structural basis that underlies the transmembrane signaling mechanism, we have overexpressed the soluble extracellular domain of the type II activin receptor from mouse (ActRII-ECD). We used the methylotrophic yeast Pichia pastoris as an expression host to produce a large quantity of ActRII-ECD. Expression was carried out in a fermentor with a typical yield of 10 mg of pure ActRII-ECD from a liter of growth media. Biological function was confirmed by the ability to decrease the activin-stimulated release of FSH from cultured rat pituitary cells in addition to several activin-binding assays, including native gel shift and chemical cross-linking. The glycosylation on ActRII-ECD was shown to be dispensable for high-affinity activin binding, and nonnatural sugars from the yeast expression host did not interfere with binding, indicating that the binding of activin is not sensitive to the environment near the two positions of N-linked glycosylation. Analytical ultracentrifugation of the complex between activin A and ActRII-ECD reveals that two receptors associate with one activin A dimer, consistent with results from chemical cross-linking experiments.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9843440     DOI: 10.1021/bi981939o

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  8 in total

1.  Bone morphogenetic protein-2 and -6 heterodimer illustrates the nature of ligand-receptor assembly.

Authors:  Michael J Isaacs; Yasuhiko Kawakami; George P Allendorph; Byung-Hak Yoon; Juan Carlos Izpisua Belmonte; Senyon Choe
Journal:  Mol Endocrinol       Date:  2010-05-19

2.  N-linked glycosylation of the bone morphogenetic protein receptor type 2 (BMPR2) enhances ligand binding.

Authors:  Jonathan W Lowery; Jose M Amich; Alex Andonian; Vicki Rosen
Journal:  Cell Mol Life Sci       Date:  2013-12-15       Impact factor: 9.261

3.  Characterization of the ligand binding functionality of the extracellular domain of activin receptor type IIb.

Authors:  Dianne Sako; Asya V Grinberg; June Liu; Monique V Davies; Roselyne Castonguay; Silas Maniatis; Amy J Andreucci; Eileen G Pobre; Kathleen N Tomkinson; Travis E Monnell; Jeffrey A Ucran; Erik Martinez-Hackert; R Scott Pearsall; Kathryn W Underwood; Jasbir Seehra; Ravindra Kumar
Journal:  J Biol Chem       Date:  2010-04-12       Impact factor: 5.157

4.  Structure of the ternary signaling complex of a TGF-beta superfamily member.

Authors:  George P Allendorph; Wylie W Vale; Senyon Choe
Journal:  Proc Natl Acad Sci U S A       Date:  2006-05-03       Impact factor: 11.205

5.  Activin potentiates proliferation in mature avian auditory sensory epithelium.

Authors:  Jennifer S McCullar; Sidya Ty; Sean Campbell; Elizabeth C Oesterle
Journal:  J Neurosci       Date:  2010-01-13       Impact factor: 6.167

6.  Production, Isolation, and Structural Analysis of Ligands and Receptors of the TGF-β Superfamily.

Authors:  Tao Huang; Andrew P Hinck
Journal:  Methods Mol Biol       Date:  2016

Review 7.  Recombinant protein expression in Pichia pastoris.

Authors:  J M Cregg; J L Cereghino; J Shi; D R Higgins
Journal:  Mol Biotechnol       Date:  2000-09       Impact factor: 2.860

8.  Structural insights into the evolution of a sexy protein: novel topology and restricted backbone flexibility in a hypervariable pheromone from the red-legged salamander, Plethodon shermani.

Authors:  Damien B Wilburn; Kathleen E Bowen; Kari A Doty; Sengodagounder Arumugam; Andrew N Lane; Pamela W Feldhoff; Richard C Feldhoff
Journal:  PLoS One       Date:  2014-05-21       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.